Ali Fattaey, Ph.D.

Dr. Fattaey has served as the company’s President and CEO since 2014. He joined the company in 2013 as President and Chief Operating Officer.

Previous experience:
President and CEO, ACT Biotech (acquired by Eddingpharm)                                       
VP Research, Chiron (acquired by Novartis)
Chief Scientific Officer, Sagres Discovery (acquired by Chiron)
VP Research, Onyx Pharmaceuticals (acquired by Amgen)
Research Fellow, Medicine, Harvard Medical School, Massachusetts General Hospital

PhD, Kansas State University
BS, Kansas State University


James Dentzer

Mr. Dentzer has served as the company’s CFO & Chief Operating Officer since 2018. He joined the company in 2016 as CFO.

Previous experience:
CFO, Dicerna Pharmaceuticals
CFO, Valeritas
CFO, Amicus Therapeutics
VP Corporate Controller, Biogen

MBA, University of Chicago
BA, Boston College


Robert Martell, M.D., Ph.D.

Dr. Martell has served as the company’s Head of Research & Development since 2018. He joined the company as a member of the Board of Directors in 2011.

Previous experience:
Assoc Chief of Hematology/Oncology, Tufts Medical Center                                       
Chief Medical Officer, Tesaro
Chief Medical Officer, MethylGene
Director, Oncology Global Clinical Research
Deputy Director, Medical Science Unit, Bayer

PhD, University of Michigan
MD, Wayne State University 
BA, Kalamazoo College 

Board Certified in Internal Medicine, Medical Oncology, and Hematology